DDInter624 DDInter1296
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Amiodarone
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Cytochrome P450 2C9 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Amiodarone
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Efavirenz {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Amiodarone
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Efavirenz {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Dermatitis exfoliative {u} (Side Effect) is caused by {v} (Compound) Amiodarone
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Lomitapide
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Nintedanib
Efavirenz {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Nintedanib
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Carbamazepine
Carbamazepine {u} may lead to a major life threatening interaction when taken with {v} Nintedanib
Efavirenz {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Dermatitis exfoliative {u} (Side Effect) is caused by {v} (Compound) Carbamazepine
Carbamazepine {u} may lead to a major life threatening interaction when taken with {v} Nintedanib
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Saquinavir
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Efavirenz (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) includes Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Efavirenz (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Efavirenz (Compound) causes Dermatitis exfoliative (Side Effect) and Dermatitis exfoliative (Side Effect) is caused by Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Efavirenz (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Lomitapide (Compound) and Lomitapide may lead to a major life threatening interaction when taken with Nintedanib
Efavirenz (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Nintedanib
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Nintedanib
Efavirenz (Compound) causes Dermatitis exfoliative (Side Effect) and Dermatitis exfoliative (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Nintedanib
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is upregulated by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib